Form 4: Aligos Therapeutics Director Jack Nielsen Executes Option Exchange Program
SEC Form 4
Director Jack Nielsen participated in Aligos Therapeutics' option exchange program, canceling an existing option and receiving a replacement option with a lower exercise price.
Summary
- On February 27, 2024, Aligos Therapeutics director Jack Nielsen participated in the company's option exchange program.
- Nielsen's existing option for 15,000 shares, granted on June 17, 2021, with an exercise price of $26.58, was canceled.
- On February 28, 2024, Nielsen received a replacement option for 4,411 shares with a significantly lower exercise price of $0.96 per share.
- The replacement option vests one year from the grant date, contingent on Nielsen's continued service with Aligos Therapeutics.
Sentiment
Score: 6
Explanation: The document describes a routine transaction related to executive compensation. The sentiment is neutral as it reflects an administrative action rather than a significant strategic development.
Positives
- The option exchange program may incentivize the director with a lower exercise price.
Future Outlook
The replacement option vests one year from the grant date, subject to the reporting person's continued service with the issuer.
Industry Context
Option exchange programs are sometimes used by companies to re-incentivize employees or directors when the stock price has fallen significantly below the exercise price of existing options.
Stakeholder Impact
- The option exchange program could potentially impact shareholder value depending on the future performance of the company's stock.
Key Dates
| Date | Description |
|---|---|
| 06/17/2021 | Original grant date of the canceled option for 15,000 shares. |
| 06/17/2022 | Date the original option became exercisable. |
| 02/27/2024 | Date of cancellation of the original option for 15,000 shares. |
| 02/28/2024 | Date of grant of the replacement option for 4,411 shares. |
| 06/17/2031 | Expiration date of both the original and replacement options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.